Opinion|Videos|July 17, 2023
Comparing Bispecifics and CAR T-Cell Therapy for Patients With MM
Noffar Bar, MD, shares how she would choose between the potential bispecific antibodies for treatment of multiple myeloma after recent data updates.
Advertisement
Episodes in this series
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Measured Tumor Volume on PSMA PET-CT Linked With Survival in Prostate Cancer
2
Mapping Practical Steps to Expand CAR T-Cell Access in Multiple Myeloma
3
Scaling Low-Dose Radiation Therapy for Osteoarthritis Across a Network
4
Surgery Correlates With Better Survival Vs SABR in Early-Stage NSCLC
5